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Nanotechnology has prompted new and improved materials for biomedical applications with particular emphasis in therapy
and diagnostics. Special interest has been directed at providing enhanced molecular therapeutics for cancer, where conventional
approaches do not eﬀectively diﬀerentiate between cancerous and normal cells; that is, they lack speciﬁcity. This normally
causes systemic toxicity and severe and adverse side eﬀects with concomitant loss of quality of life. Because of their small size,
nanoparticlescanreadilyinteractwithbiomoleculesbothatsurfaceandinsidecells,yieldingbettersignalsandtargetspeciﬁcityfor
diagnostics and therapeutics. This way, a variety of nanoparticles with the possibility of diversiﬁed modiﬁcation with biomolecules
have been investigated for biomedical applications including their use in highly sensitive imaging assays, thermal ablation, and
radiotherapy enhancement as well as drug and gene delivery and silencing. Here, we review the available noble metal nanoparticles
for cancer therapy, with particular focus on those already being translated into clinical settings.
1.Introduction
Cancer is one of the leading causes of mortality in the
modern world, with more than 10 million new cases every
year [1]. It is well established that cancer is a multifacto-
rial disease caused by a complex mixture of genetic and
environmental factors [2–4] ,w h e r ec o n s i d e r a b l ea d v a n c e s
have led to a more comprehensive understanding of cancer
at the genetic, molecular, and cellular levels providing new
targets and strategies for therapy [5]. Nevertheless, these
advanceshaveyettobeeﬀectivelytranslatedintofunctioning
diagnostics and therapy. For example, the eﬀectiveness of
many anticancer drugs is limited due to the inability to reach
the target site in suﬃcient concentrations and eﬃciently
exert the pharmacological eﬀect without causing irreversible
unwanted injury to healthy tissues and cells [6, 7].
The technological leap of controlling materials at nano-
scale provides for a “big revolution” in medical and health-
care treatments and therapies [8, 9]. Nanotechnology oﬀers
a wealth of tools to diagnose and treat cancer—new imaging
agents, multifunctional, targeted devices capable of bypass-
ing biological barriers to deliver therapeutic agents directly
to cells and tissues involved in cancer growth and metastasis,
monitor predictive molecular changes allowing preventive
action against precancerous cells, and minimizing costs and
side eﬀects [5, 10, 11]. Nanotechnology-based therapies for
cancer with minimal side eﬀects and high speciﬁcity are on
the surge, where the main challenge is to develop a system
for molecular therapy capable of circulating in the blood
stream undetected by the immune system and recognize
the desirable target, signaling it for eﬀective drug delivery
or gene silencing with minimum collateral cell damage—
nanovectorization. As a result, personalized medicine could
become a reality in cancer patient management.
Nanoparticles (NPs), and noble metal NPs in particular,
are versatile agents with a variety of biomedical applications
including their use in highly sensitive diagnostic assays [12,
13], thermal ablation, and radiotherapy enhancement [14–
17], as well as drug and gene delivery [18–21]. Moreover,
n o b l em e t a lN P sh a v eb e e np r o p o s e da sn o n t o x i cc a r r i e r s
for dru and gene-delivery applications [22–24]. Additionally,
the nanoparticle-based systems can provide simultaneous
diagnostic and therapy, that is, Theranostics, exploring
their unique properties for better penetration of therapeutic2 Journal of Drug Delivery
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Figure 1: Noble metal NPs for cancer therapy. Once the tumor is directly connected to the main blood circulation system, NPs can exploit
severalcharacteristicsofthenewlyformedvasculatureandeﬃcientlytargettumors.Tumorcellsaresuppliedbybloodcapillariesthatperfuse
the cells of the tissue where NPs can (i) passively accumulate or (ii) anchor through targeting moieties to biomarkers overexpress by tumor
cells. NPs can act simultaneously as therapeutic agents, inducing hyperthermia, enhancing radiotherapy, silencing genes, and/or delivering
drugs to induce tumor cell death, and as imaging enhancers or contrast agents, to help tracking the therapeutic eﬀects in real time.
moieties and tracking within the body, allowing a more
eﬃcient therapy with a reduced risk in comparison to
conventional therapies [25]—see Figure 1.
The unique characteristics of noble metal NPs, such
as high surface-to-volume ratio, broad optical properties,
ease of synthesis, and facile surface chemistry and func-
tionalization hold pledge in the clinical ﬁeld for cancer
therapeutics [22, 26, 27]. Noble metal NPs (e.g., gold,
silver, or a combination of both) present highly tunable
optical properties, which can be easily tuned to desirable
wavelengths according to their shape (e.g., nanoparticles,
nanoshells, nanorods, etc.), size (e.g., 1 to 100nm), and
composition (e.g., core/shell or alloy noble metals), enabling
their imaging and photothermal applications under native
tissue [28, 29]. These NPs can also be easily functionalized
with various moieties, such as antibodies, peptides, and/or
DNA/RNA to speciﬁcally target diﬀerent cells [30]a n dw i t h
biocompatible polymers (e.g., polyethylene glycol and PEG)
toprolongtheirinvivocirculationfordrugandgenedelivery
applications [23, 24]. Moreover, they can eﬃciently convert
light or radiofrequencies into heat, thus enabling thermal
ablation of targeted cancer cells [31, 32].
In this paper, we will focus on the application of noble
metal NPs for cancer therapy with particular emphasis on
their use in vivo and their potential to be translated into
clinical settings.
2. Therapy
In medical terms, a therapeutic eﬀect is a consequence of
a medical treatment of any kind, the results of which are
judged to be desirable and beneﬁcial [33]. Conventional
therapy methods in cancer involve the employment of agents
that do not greatly diﬀerentiate between cancerous and
normal cells, leading to systemic toxicity and adverse and
severe side eﬀects [34]. Eﬃcient in vivo targeting to hetero-
geneous population of cancer cells and tissue still requires
better selectivity and noncytotoxicity to surrounding healthy
cells. However, universally targeting cells within a tumor
is not always feasible, because some drugs cannot diﬀuse
eﬃciently and the random nature of the approach makes
it diﬃcult to control the process and may induce multiple-
drugresistance—asituationwherechemotherapytreatments
fail due to resistance of cancer cells towards one or more
drugs [7]. Making use of their extraordinary properties,
nanotechnology-based systems could oﬀer a less-invasive
alternative, enhancing the life expectancy and quality of life
of the patient [35]. Among these, the potential therapeutic
application of noble metal NPs represents an attractive
platform for cancer therapy in a wide variety of targets and
clinical settings [36, 37].
2.1. Tumor Targeting. It is expected that the greatest gains
in therapeutic selectivity will be achieved by synergistic
combinations of several multicomponent targeting strate-
gies that is capable of simultaneously target and deliver
multiple therapeutic agents while avoiding the organism’s
biological and biophysical barriers. NPs targeting strategies
to cancerous tissues have focused on passive and active
targeting. In passive targeting, because numerous tumors
present defective vasculature and poor lymphatic drainageJournal of Drug Delivery 3
duetotherapidgrowthofsolidtumors,noblemetalNPscan
extravasate into the tumor stroma through the fenestrations
of the angiogenic vasculature, demonstrating targeting by
enhanced permeation and retention, thus accumulation at
the tumor site [6, 8, 38]. Additionally, functionalization
of the NP’s surface with hydrophilic molecules, such as
PEG, can also greatly increase their solubility, help evading
macrophage-mediated uptake and, thus, avoid removal from
the systemic circulation and protect their carriers from
enzymatic degradation when used in vivo [30]. For active
targeting, NPs can be easily functionalized with a wide
variety of biological moieties, such as antibodies, peptides,
and/or DNA/RNA to speciﬁcally target extracellular and
intracellular receptors or pathways [30]. The use of NPs
functionalized with multiple peptides or antibodies, such as
monoclonal antibodies, have been described to successfully
target speciﬁc cell surface proteins or receptors on cancer
cells and further direct their antitumor action, leading to
tumor cell death with minimal damage to collateral healthy
cells [36, 39–41]. In nucleic-acid functionalized NPs, DNA
andRNAmacromoleculescanbeusedtosimultaneouslytar-
get speciﬁc sequences and exert their genetic-based therapy
[42, 43].
To help tracking noble metal NPs in vivo and enhance
the imaging properties of such moieties, leading to more
eﬃcient control of their therapeutic properties, they can also
be functionalized with chemical moieties, such as Raman
[44, 45]o rﬂ u o r e s c e n t[ 46, 47]r e p o r t e r s .
2.2. Gene Silencing. Antisense DNA [48, 49]a n dR N A
interference (RNAi) via the use of small-interfering RNA
[50–53]h a v ee m e r g e da sap o w e rf u la n du s e f u lt o o l st ob l o c k
gene function and for sequence-speciﬁc posttranscriptional
gene silencing, playing an important role in downregulation
of speciﬁc gene expression in cancer cells.
Small interfering RNAs (siRNAs) can be transfected into
mammalian cells by a variety of methods that inﬂuence the
strength and duration of the silencing response, which in
turn is aﬀected by the amount of siRNA that is delivered
and on the potential of each siRNA to suppress its target.
Thus, one drawback of using naked siRNAs is that they show
extremely short half-lives, weak protection against action by
RNases, poor chemical stability, and common dissociation
from vector [54]. In fact, the major obstacle to clinical appli-
cation is the uncertainty about how to deliver therapeutic
RNAs (e.g., miRNA and/or siRNA) with maximal therapeu-
tic impact. Nanotechnology oﬀers an unprecedented oppor-
tunity to overcome these problems, as nanoscale devices, due
to their small size, can readily interact with biomolecules on
both the surface of cells and inside of cells for longer periods
of time [10]. Gold NPs (AuNPs) have shown potential as
intracellular delivery vehicles for antisense oligonucleotides
[55] and for therapeutic siRNA by providing protection
againstRNAsesandeaseoffunctionalizationforselectivetar-
geting [42, 43]. For example, Mirkin and coworkers showed
that AuNPs attached to single-stranded oligodeoxynu-
cleotidescanbeusedforgenetherapy,providingahighlyeﬃ-
cient gene regulator in terms of high loading of the antisense
DNA with no toxicity at the concentrations studied [55].
TheyhavealsoshownthatpolyvalentRNA-AuNPconjugates
are readily taken up by cells and that the particle bound
siRNA could eﬀectively regulate genes in the context of RNA
interference [42]. AuNPs modiﬁed with the hydrophilic PEG
polymer, siRNAs and then coated with poly(β-aminoester)s
have been shown to facilitate high levels of in vitro siRNA
delivery and gene silencing in human cells [56]. Also, Braun
et al. developed an Au-nanoshell functionalized with TAT-
lipidlayerfortransfectionandselectivereleaseofsiRNA[57],
where the TAT-lipid coating was used to eﬃciently mediate
the cellular uptake of the nanoconjugates and the siRNA
release was dependent on near-infrared (NIR) laser pulses.
The authors demonstrated that this NIR strategy for siRNA
release was proﬁcient and time dependent.
SeveralotherstudiesusingengineeredNPsmodiﬁedwith
siRNA have demonstrated a cytoplasmic delivery system of
siRNA and eﬃcient gene silencing using AuNPs [42, 56, 58–
60].
2.3. Hyperthermia. Hyperthermia is based on the eﬀect
increasing temperatures have on living cells, and it is
commonly accepted that above 42◦C cell viability is strongly
reduced. In fact, hyperthermia eﬀects can range from
moderate denaturation of blood and extracellular proteins
to induction of apoptosis and, above 50◦C, to cell death
and tissue ablation [61]. Hyperthermia therapy in cancer
has been widely used either via direct irradiation or suitable
temperaturevectors,suchasmetalNP s[62].Innanoparticle-
mediated hyperthermia for cancer, NPs heat up cancerous
cells beyond their temperature tolerance limits, which are
lower than normal healthy tissue due to their poor blood
supply, killing them selectively. This can be achieved by
exposing the entire patient or the targeted area to an
alternating current magnetic ﬁeld, an intense light source
or radiofrequencies which will cause the NPs to heat up
and induce thermal ablation of the tumor. One of the
most widespread examples of hyperthermia mediated by
NPs, magnetic NPs have been introduced in the body
through magnetic delivery systems or local injection to the
aﬀected area [63]. The ﬁrst in vivo Phase II clinical trials
of magnetic NP hyperthermia were undertaken in Germany
in 2005 [64] by injecting the prostate of cancer patients
with biocompatible magnetite NPs. Successful results were
obtained using minimally invasive ablation of the tumor in
an AC magnetic ﬁeld after several sessions.
Noble metal NPs have thoroughly been used as pho-
tothermal agents for in vivo therapy as a less invasive experi-
mental technique that holds great promise for the treatment
of cancer [65]. It combines two key components: (i) light
source, such as lasers with a spectral range of 650–900nm
[66] for deep tissue penetration and (ii) optical absorbing
NPs which eﬃciently transforms the optical irradiation into
heat on a picosecond time scale, thus inducing photothermal
ablation [67, 68]. For example, Huang and coworkers
demonstrated that Au-nanorods are eﬀective photothermal
agents due to their longitudinal absorption band in the NIR
on account of their SPR oscillations [65, 66, 69]. Small diam-
eter Au-nanorods are being used as photothermal converters
of near infrared radiation (NIR) for in vivo applications due4 Journal of Drug Delivery
to their high absorption cross-sections beyond the tissue
absorptionspectra.SinceNIRlighttransmitsreadilythrough
human skin and tissue, these nanorods can be used as
ablation components for cancer [70, 71]. Other gold nanos-
tructures such as Au-nanoshells [72–74], Au-nanocages
[67, 75, 76], and spherical AuNPs [77] have also demon-
stratedeﬀectivephotothermaldestructionofcancercellsand
tissue. PEG-modiﬁed Au-nanoshells (Silica/Au core/shell
NPs) injected intravenously in tumor-bearing mice showed
to passively accumulate in the tumor tissue due to the
leakiness of the tumor vasculature. The rapid heating of Au-
nanoshells upon NIR laser irradiation allowed for eﬀective
photothermal ablation of tumor in the mouse [78]. A similar
approach was used by Terentyuk et al., where plasmonic sil-
ica/gold nanoshells were used to produce a controllable laser
hyperthermia in tissues, thus enhancing the photothermal
eﬀect in cancer cells [79]. Sirotkina et al. described the use of
AuNPs for skin tumor therapy based on local laser-inducing
hyperthermia. After intravenous injection, the AuNPs accu-
mulated in the skin tumor cells after 4-5 hours and induced
apoptotic death of tumor cells, completely inhibiting the
t u m o rg r o w t ha f t e rj u s tﬁ v ed a y so ft r e a t m e n t[ 80].
The photothermal properties of AuNPs can also be used
to generate transient vapor nanobubbles in order to produce
a tunable nanoscale theranostic agent, described as plas-
monic nanobubbles [81]. These nanobubbles are generated
when the AuNPs are locally overheated with short laser
pulses, due to the evaporation of a very thin volume of
the surrounding medium, which in turn creates a vapor
nanobubble that expands and collapses within nanoseconds.
Plasmonic nanobubbles have been successfully applied as an
in vivo tunable theranostic cellular agent in zebraﬁsh hosting
prostate cancer xenografts and in leukemia cells of human
bone marrow specimens, presenting higher therapeutic
selectivity when compared with AuNPs alone [82, 83]. The
use of noninvasive radiowaves at 13.56MHz have also been
shown to induce heat in AuNPs and thermally destroy tumor
tissue [84]. In vivo rat exposures to 35 Watts using direct
AuNPs injections resulted in signiﬁcant thermal injury at
subcutaneousinjectionsites.Radiowaveshavetheadvantage
of presenting signiﬁcantly better penetration on tissue than
NIR light, making them more eﬃcient for deeper solid
tumors [85]. Nonetheless, despite their greater depth of
penetration,thereisalsogreaterenergyattenuationbytissue.
Gold-silver-(AuAg-) nanorods labeled with molecular
aptamers proved to require up to six orders of lower laser
powerirradiationtoinducecelldeathwhencomparedtoAu-
nanoshells or Au-nanorods [86]. These aptamer Scg8-AuAg-
nanorods conjugates presented excellent hyperthermia eﬃ-
ciency and selectivity to CEM cells, exceeding the aﬃnity of
the original aptamer probes alone. Bimetallic AuAg-nano-
structures with a dendrite morphology and hollow interior
have also been developed as photothermal absorbers to
destroy A549 lung cancer cells [87]. The photothermal per-
formance of such dendrites required lower NP concentra-
tions and laser power for eﬃcient cancer cell damage when
compared to Au-nanorods photothermal therapeutic agents.
Likewise, Cheng and coworkers evaluated the photothermal
eﬃciencies of three Au-based nanomaterials (silica@Au-
nanoshells, hollow Au/Ag nanospheres and Au-nanorods) at
killing three types of malignant cells (A549 lung cancer cells,
HeLacervixcancercells,andTCCbladdercancercells)using
a CW NIR laser [88]. Silica@Au-nanoshells needed the low-
est NP concentration for eﬀective photo-ablation, whereas
hollow Au/Ag nanospheres and Au-nanorods needed incre-
asingly higher concentrations.
Gold has also been used together with magnetic or para-
magnetic materials to enhance the photothermal eﬀect and,
thus, increase cancer cell death [89, 90].
2.4. Drug Delivery. The vast majority of clinically used drugs
for cancer are low molecular-weight compounds that diﬀuse
rapidly into healthy tissues being evenly distributed within
the body, exhibit a short half-life in the blood stream and a
high overall clearance rate. As a consequence, relatively small
amounts of the drug reach the target site, and distribution
into healthy tissues leads to severe side eﬀects. Poor drug
delivery and residence at the target site leads to signiﬁcant
complications, such as multidrug resistance [91]. As seen
above, nanoparticles can be used as vectors for targeting
cancer tissue/cells so as to optimize biodistribution of drugs.
The NPs’ performance as drug vectors depends on the size
and surface functionalities of the particles, drug release rate,
and particle disintegration. These systems show evidence of
enhanced delivery of unstable drugs, more targeted distribu-
tion and capability to evade/bypass biological barriers.
AuNPs have already been used as vehicles for the delivery
of anticancer drugs, such as paclitaxel- [92]o rP l a t i n u m -
(Pt-) based drugs (e.g., cisplatin, oxaliplatin, etc.) [93, 94].
Gibsonetal.describedtheﬁrstexampleof2nmAuNPscova-
lently functionalized with the chemotherapeutic drug pacli-
taxel[92].Theadministrationsofhydrophobicdrugsrequire
molecular encapsulation, and it is found that nanosized
particles are particularly eﬃcient in evading the reticuloen-
dothelial system [95]. Gold-gold sulﬁde nanoshells covered
by a thermosensitive hydrogel matrix have been developed as
a photothermal modulated drug-delivery system [96]. These
nanoshell-composite hydrogels were designed to strongly
absorb NIR light and release multiple bursts of any soluble
material held within the hydrogel matrix in response to
repeated NIR irradiation. More recently, Yavuz and cowork-
ers developed a similar approach using 50-nm hollow Au-
nanocubes(nanocages)witheightlopped-oﬀporouscorners
coveredbyathermosensitivepolymercontainingapreloaded
eﬀector that can be later released in a controllable fashion
using an NIR laser [18].
2.5. Radiotherapy. Radiotherapy uses ionizing radiation for
cancer treatment to control the proliferation of malignant
cells. Nonetheless, the delivery of a lethal dose of radiation to
a tumor while sparing nearby healthy tissues remains the
greatest challenge in radiation therapy. Noble metal NPs
can act as antennas, providing enhanced radiation targeting
with lower radiation doses, consequently avoiding damage
to healthy tissues. The irradiation may also be used to acti-
vate the NPs and set up the release of their cytotoxic action.
AuNPs, upon X-ray irradiation, can act as dose enhancers
and/or generate radicals that damage cancer cells and induceJournal of Drug Delivery 5
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Figure 2: Multifunctional NP-based systems for tumor targeting, delivery and imaging. These innovative NPs comprise nucleic acids,
aptamers and anticancer drug molecules for delivery to the target tissue. Depending on the targeting mechanism, they can be on the surface
or inside the NPs. Responsive NPs/molecules can also trigger reaction upon external stimuli through the functionality of valuable tumor
markers, peptides, polymers and antibodies that can used to improve NP circulation, eﬀectiveness and selectivity. Multifunctional systems
can carry reporter molecules tethered to the particle surface and employed as tracking and/or contrast agents.
cell apoptosis and have been proposed as potential radiosen-
sitizers for X-ray cancer therapy [97]. The use of this strategy
has led to improvement in the treatment on cancer cells
with little or no increase in harm to normal surrounding
t i s s u e si nm i c em o d e l s[ 15] and also in breast cancer [98].
More recently, Xu and coworkers studied the potential eﬀects
on radiation-induced killing of glioma cells mediated by
10, 20, and 40nm AuNPs and 20, 50, and 100nm silver
nanoparticles (AgNPs), all modiﬁed with proteins from fetal
bovine serum [99]. Treating glioma cells with AgNPs led
to radiation dose-dependent cytotoxicity, with smaller size
particles(20and50nm)beingthemostcytotoxicatrelatively
harmless radiation doses. In this study, AuNPs showed little
eﬀect on cell survival across diﬀerent doses of ionizing
radiation, which contrasted with the results of previous
studies performed with AuNPs coated with PEG or amino
acids in mice colorectal adenocarcinoma and breast cancer
cells [15, 98]. Hypothetically, the diﬀerent coatings of the
AuNPs used may be responsible for the diﬀerent outcomes
observed.
The use of platinum NPs (PtNPs)as prominent radiation
sensitizers in radiotherapy cancer treatment showed strong
enhancement of the biological eﬃciency of radiations, lead-
ing to ampliﬁed lethal damage in DNA from tumor cells,
when compared to metal atoms [37].
3.Imaging
Along with their therapeutic capabilities, most noble metal
NPs can be used for the simultaneous actuation and tracking
in vivo—see Figure 2. Because light absorption from biologic
tissue components is minimized at near infrared (NIR)
wavelengths, most noble metal NPs for in vivo imaging and
therapy have been designed to strongly absorb in the NIR
so as to be used as eﬀective contrast agents [100]. However,
noble metal nanomaterials, such as NPs, nanoshells, nan-
oclusters,nanocages,andnanorods,haveshowedwidespread
application as contrast agents for in vivo cancer imaging:
those presenting a signiﬁcant absorbance and scattering in
the NIR region [46, 101] or surface-enhanced Raman scat-
tering (SERS) [102], or as contrast agents for computed6 Journal of Drug Delivery
tomography (CT) [103], magnetic resonance imaging (MRI)
[104], optical coherence tomography (OCT) [105–107], and
p h o t o a c o u s t i ci m a g i n g( P A I )[ 108]. Moreover, most noble
metal nanomaterials are capable of combining multiple
imaging modalities that can yield complementary informa-
tion and oﬀer synergistic advantages over any single imaging
technique [109, 110].
Three-dimensional imaging can be achieved by com-
puted tomography (CT), where a series of plane-cross-secti-
onal images along an axis are interlinked by computer to
create a 3D image. Typically, the cross-sectional images are
acquired using X-ray radiation involving larger radiation
doses than the conventional X-ray imaging procedures,
which could lead to increased risk to public health [111].
The use of ∼30nm PEG-coated AuNPs for in vivo CT con-
trast agent was shown to increase image contrast, which
allows to reduce the radiation dosage needed, allow to
overcome the limitations of conventional contrast agents
(e.g., iodine-based compounds), such as short imaging times
due to rapid renal clearance, renal toxicity, and vascular
permeation [103]. Hybrid NPs with a super-paramagnetic
iron oxide/silica core and a gold nanoshell, with signiﬁcant
absorbance and scattering in the NIR region, have been used
invivoasdualcontrastagentsforCTandmagneticresonance
imaging (MRI) presenting high CT attenuation and a good
MR signal in hepatoma, compensating for the weakness of
each modality [112].
Optical coherence tomography (OCT) is an imaging
modality that provides cross-sectional subsurface imaging of
biological tissue with micrometer scale resolution. The extra
scattering achieved by using Au-nanoshells has been shown
to provide an enhanced optical contrast and brightness for
improved diagnostic imaging of tumors in mice due to the
preferential accumulation of the nanoshells in the tumor.
[78]. Tseng et al. developed nanorings with a localized
surface plasmon resonance covering a spectral range of
1300nm that produced both photothermal and image
contrast enhancement eﬀects in OCT when delivered into
pig adipose samples [113]. Moreover, the image contrast
enhancement eﬀect could be isolated by continuously
scanning the sample with a lower scan frequency, allowing to
eﬀectively control the therapeutic modality. Similarly, gold
capped nanoroses have been used in photothermal OCT to
detect macrophages in ex vivo rabbit arteries [114].
Photoacoustic imaging (PAI) and photoacoustic tomog-
raphy (PAT) are noninvasive imaging techniques capable of
resolving the optical absorption map of tissue at penetration
depths akin with ultrasound imaging. Wang and coworkers
have used this technique to image the distribution of Au-
nanoshells circulating in the vasculature of a rat brain by
achieving a gradual enhancement of the NIR optical absorp-
tioninthebrainvessels[115].TheseAu-nanocagesenhanced
the contrast between blood and the surrounding tissues
by up to 81%, allowing a more detailed image of vascular
structures at greater depths. Additionally, these nanocages
were shown to be better suited for in vivo applications,
specially due to their more compact size (<50nm compared
to >100nm for Au-nanoshells) and larger optical absorption
crosssectionswhencomparedtoAu-nanoshells.Gold-nano-
rods show the maximum of the plasmon resonance tuned
further into the NIR that allowed Motamedi et al. to develop
a contrast agent for a laser optoacoustic imaging system
for in vivo detection of gold nanorods and to enhance the
diagnostic power of optoacoustic imaging [116]. Song et al.
proposed a noninvasive in vivo spectroscopic photoacoustic
sentinel lymph node mapping using gold nanorods as lymph
node tracers in a rat model [117].
Also, noble metal NP probes can be used for in situ
diagnosticsofcancer.Forexample,NP-basedNIRprobescan
overcome several limitations of conventional NIR organic
dyes, such as poor hydrophilicity and photostability, low
quantum yield and detection sensitivity, insuﬃcient sta-
bility in biological systems, and weak multiplexing capa-
bility. Additionally, the high scattering properties of these
NPs can enhance contrast of imaging systems based on
microscopy, such as dark-ﬁeld or dual-photon lumines-
cence microscopy. Zhang et al. developed ﬂuorescent metal
nanoshells as molecular imaging agents to detect single
microRNA (miRNA) molecules in lung cancer cells [47].
These metal nanoshells were composed of silica spheres
with encapsulated Ru(bpy)3
2+ complexes as core and thin
silver layers as shell. The silver shell allowed to enhance
emission intensity up to 6-fold and photostability by 2-fold,
as well as to achieve longer lifetime emission signals that
overcome cellular autoﬂuorescence interference. Loo et al.
demonstrated the use of NIR scattering Au-nanoshells as a
contrast agent in dark-ﬁeld microscopy to target antihuman
epidermal growth factor receptor 2 (HER2), a clinically
signiﬁcant breast cancer molecular marker [72]. These Au-
nanoshells were also used by Bickford et al. for imaging
live HER2-overexpressing cancer cells using two-photon
microscopy [118].
Surface-enhanced Raman scattering (SERS) using Au-
or AgNPs with an attached reporter species with a Raman
signature can be explored to highlight cellular structures
and provide molecular structural information on the cellular
environment in live cells [119, 120]. The use of such NPs
allows for higher spectral speciﬁcity, multiplex capabili-
ties, improved contrast and photostability to Raman-based
imaging techniques. In situ monitoring of photothermal
nanotherapy of LNCaP human prostate cancer cells by SERS
was a signiﬁcant enhancement of the Raman signal intensity
by several orders of magnitude that have been observed [44].
4.Toxicity
Both in vivo and in vitro, nanoparticles have a tendency to
accumulate within various types of cells with special aﬃnity
for macrophage-type cells (both histiocytes and blood
phagocyticcells)andreticuloendothelialcellsthroughoutthe
body. They also produce varying degrees of bioaccumulation
in such tissues as lymph nodes, bone marrow, spleen,
adrenals, liver, and kidneys [121–123]. The NPs size plays
an important role in avoiding immune activation and
renal clearance, thus enhancing their circulating time and
availability for eﬀective therapy. For example, hydrophilic
NPs ranging in size between 10 and 100nm are small enough
to slow down activation of the mononuclear phagocyteJournal of Drug Delivery 7
system but are big enough to avoid renal ﬁltration [8].
Research shows that NPs can stimulate and/or suppress
the immune responses and that their compatibility with
the immune system is largely determined by their surface
chemistry.Infact,theinﬂuenceofsize,solubility,andsurface
modiﬁcation on the biocompatibility of NPs and their use in
biological applications is well known [122]. In terms of acute
toxic eﬀects to cells, noble metal NPs have been shown to
induce DNA damage and oxidative damage [124–126].
Generally, AuNPs are considered to be benign, but the
size similarity to biological molecules could provide “cam-
ouﬂage” to cellular barriers, leading to undesired cellular
entrywhichmightbedetrimentaltonormalcellularfunction
[127]. A systematic investigation of the size-dependent
cytotoxicity of AuNPs against four cell lines found that 1
to 2nm AuNPs displayed cell-type-dependent cytotoxicity
with high micromolar IC50s, whereas 15nm AuNPs were
nontoxic to cells at concentrations 60-fold higher than the
IC50 of the smaller AuNPs [128]. These results seemed
to conﬁrm size-dependent toxicity of AuNPs, an inference
that has hitherto been shown to be somewhat ambivalent
[129–134]. In fact, Yen et al. showed that AuNPs, especially
those of smaller sizes, dramatically led to a decrease in the
population of the macrophages and upregulated the expres-
sions of proinﬂammatory genes interlukin-1, interlukin-6,
and tumor necrosis factor alpha [135]. Sun et al. studied
the in vivo toxicity of AuNPs according to their shape in
KM mice showing that rod-shaped AuNPs were the most
toxic, followed by cube-shaped AuNPs, while sphere-shaped
AuNPs displayed the best biocompatibility, revealing that
toxicity is shape dependent. Moreover, this study revealed
that all AuNPs accumulated preferentially in the liver and
spleen organs [136]. Nonetheless, it is worth pointing out
that CTAB (a cationic surfactant commonly used for Au-
nanorods synthesis) was also recently pointed out as the
source of Au-nanorods’ cytotoxicity, which may explain their
toxicity in the previous studies [137].
Silver NPs are generally considered more toxic than
AuNPs, with several studies showing that cell exposure
to AgNPs induced signiﬁcant cytotoxicity [138–141]. Con-
versely, Yen et al. determined a lower cytotoxicity of AgNPs
than that of the AuNPs and attributed this diﬀerence to
the surface charges between NPs, which can explain the
discrepancy with other studies related to AgNPs cytotoxicity
[135].
Asforplatinum,thecytotoxicityof5–8nmPtNPscapped
with polyvinyl alcohol (PVA) has been addressed in human
cells, where PtNPs were shown to enter the cells through dif-
fusion, leading to an increase in DNA damage, proliferating
cell nuclear antigen-mediated growth arrest and apoptosis
[126]. Asharani et al. performed a comparison between
toxicity of 3–10nm Pt-, 5–35nm Ag-, and 15–35nm AuNPs
capped with PVA in developing zebraﬁsh embryos, conclud-
ingthatAgNPswerethemosttoxic,followedbyPtNPs,while
AuNPs presented no indication of toxicity [142].
Even though we have focused our attention on the toxi-
city aspects of the diﬀerent noble metal nanoparticles based
mainly on size and metal, attention should also be brought
upon other properties of the nanoconjugates, such as surface
chemistry, shape, and administration pathways. In fact,
surface chemistry (e.g., functionalization with biomolecules,
stabilizers, etc.) constitutes another interface of interaction
with the organism’s proteins and cells, which in term may be
associated with unspeciﬁc adsorption or speciﬁc recognition
by the immune system, thus contributing to the overall
eﬀects of the use of the nanoparticles. The interaction with
the immune system contributes not only for the speciﬁcity
of the targeting (passive and/or active), but also towards
the toxicological eﬀect of nanoconjugates (see [122]a n d
references therein).
5. Conclusions
Nanotechnology has provided for novel and powerful sys-
tems that may be used treatment and diagnostic of cancer. In
vivodemonstrationsofnoblemetalNPsastheranosticagents
arenowemergingandserveasimportantmilestonestowards
clinical application. Nonetheless, the majority of products,
reagents and drugs being used for the development of these
nanoscale theranostic agents have still to be approved by the
main supervising agencies, such as the FDA and EMA. Thus
far, there are some questions whose answers still provide
no clear understanding about the design and application
of NPs, such as pharmacokinetics, biodistribution and side
eﬀects of the nanotherapy, and safety proﬁle of NPs before
and after conjugation and toxicity [10]. Are noble metal
NPs cytotoxic or biocompatible? And how can the NPs be
design to avoid these eﬀects? These seem to question more
diﬃculttoanswerthanpreviouslybelieved.Mosttherapeutic
and imaging approaches based on noble metal NPs rely
on AuNPs, mostly due to their higher level of nontoxicity.
Nonetheless, a more comprehensive application of core/shell
or alloy noble metal NPs, that may allow combination of
the beneﬁts of each noble metal into a single carrier, is still
to be thoroughly addressed. Even though there is not any
general mechanism for making NPs universally “nontoxic”
to all living cells and all organisms, there are important
ﬁndings that can be applied for increasing nanoparticle
biocompatibility and reducing cytotoxic interactions in vivo
and in vitro. In general, using the lowest NP dose to
get the desired response for the shortest period of time
seems to promote biocompatibility. The coating/capping
of a nanoparticle is also of the utmost relevance, since a
noncontinuous covering, the presence of cracks, roughness,
or interruptions could lead to complement or antibody
attachment, or dissolution of the coating by cell digestion,
decreasing bioavailability at target cell [143]. It is essential to
test nanoparticle/biological interactions experimentally and
modify the NPs for best biocompatibility with the cell in
order to eliminate damage to healthy tissue, guarding against
alterations in genetic/molecular function while killing the
abnormal cells. When interpreting NPs interactions with
biological cells and organisms, it is important to remember
that living systems may appear normal and be capable of
growth and function, but they may be genetically altered
in subtle ways following NP exposure, which can produce
serious consequences at some time in the distant future, such
as cancer itself.8 Journal of Drug Delivery
Noble metal nanoparticles have shown to be powerful
tools against cancer though still in need of further optimiza-
tion and characterization for full understanding of their
whole potential. It is now time to start translating these pro-
mising platforms to the clinical settings towards widespread
eﬀective therapy strategies in the ﬁght against cancer.
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